Agenda
8:45-9:00 am – Welcome
9:00-10:00 am – Treatment of Major Depression – Charles DeBattista, M.D.
10:00-11:00 am – Approaches to Managing Bipolar Disorder – Alan Schatzberg, M.D.
11:00 -11:15 am – Break
11:15-12:15 pm – Treatment of Anxiety Disorders – Charles Nemeroff, M.D., Ph.D.
12:15-1:45 pm – Lunch Break
1:45-2:45 pm – Treatment of Schizophrenia – Rona Hu, M.D.
2:45-3:45 pm – Managing Insomnia and Other Sleep Disorders – Rafael Pelayo, M.D.
3:45-4:00 pm – Break
4:00-5:00 pm – Psychopharmacologic Treatment of Children and Adolescents – Manpreet Singh, M.D., M.S.
5:00-5:10 pm – Adjournment
Description
Clinical psychopharmacology has become a major component of psychiatric practice. This course primarily provides an update for clinicians who have experience in the practice of psychopharmacology. Recent development of newly available agents as well as drugs still under study are changing practice by providing agents with unique mechanisms of action. This course will review the current status and the anticipated changes of the field in a series of lectures with questions and answers as well breakout sessions at the end of the formal presentations. The Course will include presentations on: the treatment of depression; management of bipolar disorder; psychopharmacology of post-traumatic stress disorder; treatment of patients with schizophrenia; pharmacologic approaches to children and adolescents; and the treatment of insomnia and other sleep disorders. Questions will be answered at the end of each presentation and there will be case-oriented breakout sessions with speakers at the end of the course day.
Learning Objectives
- apply a sequential treatment approach to patients with refractory major depression
- have a working knowledge on the status of antidepressants in development—e.g., psychedelics
- select optimal treatment approaches for patients with insomnia and other sleep disorders
- implement treatment strategies for bipolar disorder, schizophrenia and childhood and adolescent disorders
Faculty and Planner Disclosures
The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Program Planners
The following planners have no relevant financial relationships to disclose:
Eric R. Williams, M.D., Vikas Gupta, M.D., M.P.H., John Luo, M.D., Tanuja Gandhi, M.D., Jacques H. Ambrose, M.D., M.P.H., Philip Candilis, M.D., Carlyle Hung-Lun Chan, M.D., Akira Sawa, M.D., Danielle Hairston, M.D., Luming Li, M.D., Nina Kraguljac, D.O., Nhi-Ha T. Trinh, M.D., M.P.H., Art C. Walaszek, M.D., David Beckert, Catherine Crone, M.D., Josepha A. Cheong, M.D., Venkata Kolli, M.B., B.S., Hector Colon-Rivera, M.D., Xiaoduo Fan, M.D., Carlos Fernandez-Robles, M.D., M.B.A., Ronald Winchel, M.D., Raman Marwaha, M.D., Farah Zaidi, M.D., Gene Nakajima, M.D., Dora-Linda Wang, M.D., Cynthia Turner-Graham, M.D., Edmond T. Pi, M.D., Dhruv R. Gupta, M.D., M.S., Avani K. Patel M.D., Jessica Mayer, M.D., Vanita Sahasranaman, M.D., Eric Jarmon, D.O., M.S.C., Sudhakar Shenoy, M.D., Monica J. Taylor-Desir, M.D., M.P.H., Joseph Cullen Truett, D.O., J. Michael Bostwick, M.D., Dionne Hart, M.D., Sofia Matta, M.D., Arnaldo Moreno, M.D., Karen B. Rosenbaum, M.D., Lorenzo Norris, M.D., Donald Brandon Prunty
Faculty
The below faculty have the following relevant financial relationships to disclose:
Charles DeBattista, M.D. – Consultant/Advisory Board – Sage Therapeutics, AbbVie Pharmaceutical, Grant/Research Support - ANeurotech, AltoNeuroscience, Magnus, NeuroWell, Parexel
Charles Nemeroff, M.D., Ph.D. – Consultant/Advisory Board – Janssen, Sage Therapeutics, Inc., Goodcap Pharmaceuticals Inc,ITI, Inc,LUCY Scientific Discovery, Relmada Therapeutics, Inc,Senseye Inc, Precisement Health, Stock/Stock Options – Xhale, Corcept Therapeutics, Seattle Genetics,BI Gen Holdings Ince, EMA Wellness, Precisement Health, Relmada Therapeutics, Inc
Rafael Pelayo, M.D. – Consultant/Advisory Board - Idorsia
Manpreet Singh, M.D., M.S. - Consultant/Advisory Board – Janssen, Sunovion Pharmaceuticals Inc., AbbVie Pharmaceutical, Alkermes, Boehringer Ingelheim Pharmaceuticals, Intracellular Therapies, Alto Neuroscience, Neumora, Karuna Therapeutics, Inc., Skyland Trail, honoraria from the American Academy of Child and Adolescent Psychiatry, royalties from American Psychiatric Association Publishing and Thrive Global.
Alan Schatzberg, M.D. – Consultant/Advisory Board – Brackey Pharmaceuticals, Delpor Technology, McKinsey Pharmaceuticals, Otsuka Pharmaceuticals, Sage Therapeutics, Inc., ANeurotech, AltoNeuroscience, Magnus, NeuroWell, Parexel, Stock/Stock Options – Corcept Therapeutics, Delpor Technology, Merck & Co., Titan Pharmaceuticals, Xhale, ANeurotech
Rona Hu, M.D. has no relevant financial relationships to disclose.
Participants who wish to earn AMA PRA Category 1 Credit™ may do so after completing all sections of the course including the evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the completion date and hours earned.
Continuing Education Credit
In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The APA designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Access to the Self-Assessment and Evaluation:
To gain access to the digital course book, course evaluation, and other information about this course, please follow the steps below:
- Go to https://education.psychiatry.org/Users/InvitationCode.aspx
- Log into your APA Learning Center account or create one for free
- Paste the following Invitation Code into the text field
- Invitation code = AM24MC104
- Click “Enroll”
- Click the blue “Get Started" button on the right-hand side of the screen
- View Course Materials and complete the Course Evaluation
- Please note: Course Evaluations will not be available to complete until the in-person session at Annual Meeting 2024 has concluded.
For any questions about course access or issues with the course, please contact learningcenter@psych.org
Continuing Certification
THE AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY HAS REVIEWED THE Master’s Course in Clinical Psychopharmacology AND HAS APPROVED THIS ACTIVITY AS PART OF A COMPREHENSIVE SELF-ASSESSMENT (SA) CME ACTIVITY, WHICH IS MANDATED BY THE ABMS AS A NECESSARY COMPONENT OF CONTINUING CERTIFICATION.
Please use this link https://education.psychiatry.org/Users/InvitationCode.aspx to access the self-assessment in the APA Learning Center.
In the event that you didn’t get the opportunity to take the self-assessment before the course, the Continuing Certification activity will be accessible following the live Master Course, after 5:00 PM ET, May 8, 2024 through December 31, 2024, 11:59 PM ET.
Please note APA reports CME and Continuing Certification completion data on behalf of our members directly to ABPN, however, diplomates are still required to log on to their ABPN Physician Portal at least once per calendar year to attest to completion of their Continuing Certification activities.